<?xml version='1.0' encoding='utf-8'?>
<document id="27384319"><sentence text="Desirable Characteristics of Hepatitis C Treatment Regimens: A Review of What We Have and What We Need." /><sentence text="There have been dramatic advancements in the treatment of chronic hepatitis C (HCV) infection" /><sentence text=" This is largely due to the approval of several direct-acting antiviral agents (DAAs) from a variety of medication classes with novel mechanisms of action" /><sentence text=" These therapies are a welcomed advancement given their improved efficacy and tolerability compared to pegylated interferon and ribavirin (RBV)-based regimens"><entity charOffset="128-137" id="DDI-PubMed.27384319.s4.e0" text="ribavirin" /><entity charOffset="139-142" id="DDI-PubMed.27384319.s4.e1" text="RBV" /><pair ddi="false" e1="DDI-PubMed.27384319.s4.e0" e2="DDI-PubMed.27384319.s4.e0" /><pair ddi="false" e1="DDI-PubMed.27384319.s4.e0" e2="DDI-PubMed.27384319.s4.e1" /></sentence><sentence text=" These convenient, all-oral regimens treat a variety of genotypes and often offer high cure rates in a variety of HCV-infected populations" /><sentence text=" While there are several benefits associated with these therapies, there are also notable shortcomings" /><sentence text=" Shortcomings include diminished response or need for adjunctive RBV in difficult-to-treat populations (decompensated cirrhosis, active substance abuse patients, advanced kidney disease, etc"><entity charOffset="65-67" id="DDI-PubMed.27384319.s7.e0" text="RBV" /></sentence><sentence text="), activity against select genotypes, substantial drug-drug interaction potential, and high cost" /><sentence text=" Therefore, while current DAA-based therapies have several favorable attributes, each also has its limitations" /><sentence text=" The purpose of this review is to (1) identify the characteristics of an ideal HCV treatment regimen, (2) describe desirable features of existing regimens, (3) summarize limitations of existing regimens, and (4) introduce promising emerging therapies" /><sentence text=" This manuscript will serve as a guide for evaluating the caliber of future HCV treatment regimens" /><sentence text=" " /></document>